Emerging RAS-directed therapies for cancer

Abstract

RAS oncogenes are the most commonly mutated oncogenes in human cancer, and RAS-mutant cancers represent a major burden of human disease. Though these oncogenes were discovered decades ago, recent years have seen major advances in understanding of their structure and function, including the therapeutic and prognostic significance of diverse isoforms. Targeting of these mutations has proven difficult, despite some successes with inhibition of RAS effector signalling. More recently, direct RAS inhibition has been achieved in a trial setting. While this has yet to be translated to everyday clinical practice, this development carries much promise. This review summarizes the diverse approaches that have been taken to RAS inhibition and then focuses on the most recent developments in direct inhibition of KRAS(G12C).

Keywords

Ras / pancreatic / targeted / signalling / isoform / erk / inhibition

References

[1] Harvey JJ.An unidentified virus which causes the rapid production of tumours in mice.Nature1964;204:1104-5

[2] Kirsten WH.Morphologic responses to a murine erythroblastosis virus. J Natl Cancer Inst 1967;39:311-35.

[3] Jones S,Parsons DW.Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.Science2008;321:1801-6 PMCID:PMC2848990

[4] Cox AD,Kimmelman AC,Der CJ.Drugging the undruggable RAS: Mission possible?.Nat Rev Drug Discov2014;13:828-51 PMCID:PMC4355017

[5] Kwong LN.Targeted therapy for melanoma: rational combinatorial approaches.Oncogene2014;33:1-9

[6] Polivka J Jr.Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.Pharmacol Ther2014;142:164-75

[7] Cromm PM,Grossmann TN.Direct Modulation of Small GTPase Activity and Function.Angew Chem Int Ed Engl2015;54:13516-37

[8] Karnoub AE.Ras oncogenes: split personalities.Nat Rev Mol Cell Biol2008;9:517-31 PMCID:PMC3915522

[9] Colicelli J.Human RAS superfamily proteins and related GTPases.Sci STKE2004;2004:RE13 PMCID:PMC2828947

[10] Weinberg RA. The biology of cancer. 2nd ed. New York, NY: Garland Science; 2014.

[11] Pylayeva-Gupta Y,Bar-Sagi D.RAS oncogenes: weaving a tumorigenic web.Nat Rev Cancer2011;11:761-74 PMCID:PMC3632399

[12] Coelho MA,Rana S.Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.Immunity2017;47:1083-1099.e6 PMCID:PMC5746170

[13] Tuveson DA,Willis NA.Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects.Cancer Cell2004;5:375-87

[14] Guerra C,Dhawahir A.Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context.Cancer Cell2003;4:111-20

[15] Murugan AK,Tsuchida N.RAS mutations in human cancers: Roles in precision medicine.Semin Cancer Biol2019;59:23-35

[16] Mengoli MC,Bertolini F,Rossi G.K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.Lung Cancer2016;93:55-8

[17] Martinelli E,Troiani T.Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.Cancer Treat Rev2017;53:61-9

[18] Marks JL,Zhou Q.Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.J Thorac Oncol2008;3:111-6

[19] Cadranel J,Faller M.Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).J Thorac Oncol2012;7:1490-502

[20] Berndt N,Sebti SM.Targeting protein prenylation for cancer therapy.Nat Rev Cancer2011;11:775-91 PMCID:PMC4037130

[21] Morgillo F.Lonafarnib in cancer therapy.Expert Opin Investig Drugs2006;15:709-19

[22] Wong NS,Rosen LS.A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.Cancer Invest2011;29:617-25 PMCID:PMC4101887

[23] Milojkovic Kerklaan B,Le Tourneau C.Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.Cancer Chemother Pharmacol2013;71:53-62

[24] Lobell RB,Abrams MT.Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.Cancer Res2001;61:8758-68

[25] Whyte DB,Hockenberry TN.K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors.J Biol Chem1997;272:14459-64

[26] Gilardi M,Proietto M.Tipifarnib as a Precision Therapy for.HRAS19:1784-96 PMCID:PMC7484242

[27] Furuse J,Okano N.An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors.Cancer Chemother Pharmacol2018;82:511-9 PMCID:PMC6105164

[28] Marín-Ramos NI,López-Rodríguez ML.Blocking Ras inhibition as an antitumor strategy.Semin Cancer Biol2019;54:91-100

[29] Santra T,Rodriguez J.An Integrated Global Analysis of Compartmentalized HRAS Signaling.Cell Rep2019;26:3100-3115.e7

[30] Prior IA.Ras trafficking, localization and compartmentalized signalling.Semin Cell Dev Biol2012;23:145-53 PMCID:PMC3378476

[31] Volinsky N.Complexity of receptor tyrosine kinase signal processing.Cold Spring Harb Perspect Biol2013;5:a009043 PMCID:PMC3721286

[32] Karapetis CS,Jonker DJ.K-ras mutations and benefit from cetuximab in advanced colorectal cancer.N Engl J Med2008;359:1757-65

[33] Amado RG,Peeters M.Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.J Clin Oncol2008;26:1626-34

[34] Benvenuti S,Di Nicolantonio F.Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.Cancer Res2007;67:2643-8

[35] Mao C,Liao RY.KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.Lung Cancer2010;69:272-8

[36] Moll HP,Musteanu M.Afatinib restrains K-RAS-driven lung tumorigenesis.Sci Transl Med2018;10:eaao2301

[37] Kruspig B,Neidler S.The ERBB network facilitates KRAS-driven lung tumorigenesis.Sci Transl Med2018;10:eaao2565 PMCID:PMC6881183

[38] Castellano E.RAS Interaction with PI3K: More Than Just Another Effector Pathway.Genes Cancer2011;2:261-74 PMCID:PMC3128635

[39] Binimetinib, and Cetuximab in.BRAF382:876-8

[40] Planchard D,Groen HJM.Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.Lancet Oncol2016;17:984-93

[41] Rauch N,Kolch W.MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance.Curr Opin Struct Biol2016;41:151-8

[42] Jambrina PG,Pilkington R.Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation.Angew Chem Int Ed Engl2016;55:983-6 PMCID:PMC4736688

[43] Rukhlenko OS,Krstic A.Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling.Cell Syst2018;7:161-179.e14 PMCID:PMC6149545

[44] Hatzivassiliou G,Yen I.RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.Nature2010;464:431-5

[45] Peng SB,Kaufman MD.Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.Cancer Cell2015;28:384-98

[46] Nakamura A,Tsuchiya S.Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.Cancer Res2013;73:7043-55

[47] Robert C,Stroyakovskiy D.Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.N Engl J Med2019;381:626-36

[48] Hatzivassiliou G,Chen H.Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.Nature2013;501:232-6

[49] Bodoky G,Spigel DR.A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.Invest New Drugs2012;30:1216-23

[50] Bennouna J,Valladares-Ayerbes M.A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens.Invest New Drugs2011;29:1021-8

[51] Hainsworth JD,Kanarev V.A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.J Thorac Oncol2010;5:1630-6

[52] Kinsey CG,Boespflug AM.Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.Nat Med2019;25:620-7

[53] Yang S,Contino G.Pancreatic cancers require autophagy for tumor growth.Genes Dev2011;25:717-29 PMCID:PMC3070934

[54] Rahib L,Ocean AJ.Use of a real-world data approach to rapidly generate outcomes data following a case study of a novel treatment combination in pancreatic adenocarcinoma.J Clin Oncol 2020;38:e16735

[55] Moschos SJ,Hwu WJ.Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.JCI Insight2018;3:92352 PMCID:PMC5916243

[56] Merchant M,Schaefer G.Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors.PLoS ONE2017;12:e0185862 PMCID:PMC5628883

[57] Weekes C,LoRusso P.A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.Oncologist2020;25:833-e1438 PMCID:PMC7543243

[58] Varga A,Hollebecque A.A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.Clin Cancer Res2020;26:1229-36

[59] Sullivan RJ,Janku F.First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.Cancer Discov2018;8:184-95

[60] Bhagwat SV,Cai S.ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine.Mol Cancer Ther2020;19:325-36

[61] Burrows F,Chen J.Abstract 5168: KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors.Cancer Research2017;77 (13 Supplement):5168

[62] Britten CD.PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.Cancer Chemother Pharmacol2013;71:1395-409

[63] Belmont PJ,McKee TD.Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.Sci Signal2014;7:ra107

[64] Mohan S,Shah S.MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.Clin Cancer Res2015;21:3946-56 PMCID:PMC4558307

[65] Shapiro GI,Kwak E.Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.Invest New Drugs2020;38:419-32

[66] Aoki M,Bellacosa A,Vogt PK.The akt kinase: molecular determinants of oncogenicity.Proc Natl Acad Sci U S A1998;95:14950-5 PMCID:PMC24556

[67] Tolcher AW,Valero V.Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.Cancer Chemother Pharmacol2020;85:673-83

[68] Kessler D,Böttcher J.Drugging all RAS isoforms with one pocket.Future Med Chem2020;12:1911-23

[69] Kessler D,Mantoulidis A.Drugging an undruggable pocket on KRAS.Proc Natl Acad Sci U S A2019;116:15823-9 PMCID:PMC6689897

[70] Taveras A,Doll R.Ras oncoprotein inhibitors: The discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex.1997;5:125-33

[71] Karaguni IM,Debruyne P.The new sulindac derivative IND 12 reverses Ras-induced cell transformation.Cancer Res2002;62:1718-23

[72] Lim SM,Ficarro SB.Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.Angew Chem Int Ed Engl2014;53:199-204 PMCID:PMC3914205

[73] Ostrem JM,Sos ML,Shokat KM.K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.Nature2013;503:548-51 PMCID:PMC4274051

[74] Gehringer M.Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.J Med Chem2019;62:5673-724

[75] Janes MR,Li LS.Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.Cell2018;172:578-589.e17

[76] Patricelli MP,Li LS.Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.Cancer Discov2016;6:316-29

[77] Canon J,Saiki AY.The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.Nature2019;575:217-23

[78] Hong DS,Strickler JH.KRAS^G12C Inhibition with Sotorasib in Advanced Solid Tumors.N Engl J Med2020;383:1207-17 PMCID:PMC7571518

[79] Saiki AY,Rex K.Discovery and in vitro characterization of AMG 510-a potent and selective covalent small-molecule inhibitor of KRAS^G12C [abstract]. Proceedings of AACR Annual Meeting; 2019 Mar 29-Apr 3; Atlanta, GA; 2019.

[80] Hallin J,Hargis L.The KRAS^G12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.Cancer Discov2020;10:54-71 PMCID:PMC6954325

[81] Jänne PA,Spira A. KRYSTAL-1: updated safety and efficacy data with Adagrasib (MRTX849) in NSCLC With KRAS^G12C mutation from a phase 1/2 study. Available from: https://www.mirati.com/wp-content/uploads/Janne-849-001_NSCLC-ENA-Presentation_25Oct2020_FINAL.pdf [Last accessed on 7 Apr 2021]

[82] Welsch ME,Chambers JM.Multivalent Small-Molecule Pan-RAS Inhibitors.Cell2017;168:878-889.e29 PMCID:PMC5362268

[83] Nakamura K,Nakao K.Partial functional overlap of the three ras genes in mouse embryonic development.Oncogene2008;27:2961-8

[84] Hennig A,Esparza-Franco MA,Rubio I.Ras activation revisited: role of GEF and GAP systems.Biol Chem2015;396:831-48

[85] Freedman TS,Friedland GD.A Ras-induced conformational switch in the Ras activator Son of sevenless.Proc Natl Acad Sci U S A2006;103:16692-7 PMCID:PMC1629002

[86] Jeng HH,Bar-Sagi D.Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis.Nat Commun2012;3:1168 PMCID:PMC3640996

[87] Hunter JC,Carrasco MA,Gondi S.Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.Mol Cancer Res2015;13:1325-35

[88] Hofmann MH,Ramharter J.BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.Cancer Discov2020; PMCID:PMC7892644

[89] Shi ZQ,Park M,Feng GS.Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity.Mol Cell Biol2000;20:1526-36 PMCID:PMC85329

[90] Rauen KA.The RASopathies.Annu Rev Genomics Hum Genet2013;14:355-69 PMCID:PMC4115674

[91] Dance M,Salles JP,Raynal P.The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway.Cell Signal2008;20:453-9

[92] Sun X,Gunawan S.Selective inhibition of leukemia-associated SHP2^E69K mutant by the allosteric SHP2 inhibitor SHP099.Leukemia2018;32:1246-9 PMCID:PMC6166654

[93] Chen YN,Chan HM.Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.Nature2016;535:148-52

[94] De Roock W,Di Nicolantonio F.Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.JAMA2010;304:1812-20

[95] LoRusso PM.One Step at a Time - Clinical Evidence That KRAS Is Indeed Druggable.N Engl J Med2020;383:1277-8

[96] Kim D,Lito P.Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients.Cell2020;183:850-9 PMCID:PMC7669705